CMO Evonik acquires silica business for $630m

By Melissa Fassbender

- Last updated on GMT

Silica are small particles based on silicon dioxide used in a variety of industries. (Image: iStock/olando_o)
Silica are small particles based on silicon dioxide used in a variety of industries. (Image: iStock/olando_o)

Related tags Board of directors

Evonik Industries AG has acquired the silica business from the US company J.M. Huber, expanding the company’s presence in North America and Asia.

According to the company, Evonik’s silica products​ are being applied as flow additives and carriers for the manufacture of pharmaceuticals, as well as foodstuffs and cosmetics.

Christian Kullmann, Executive Board Member for Strategy at Evonik, commented in a release, “Combining the complementary silica businesses of Evonik and Huber will strengthen an important pillar of our portfolio​.”

Kullmann also added that Huber Silica is an “excellent regional fit with its focus on the U.S., China and India​.”

For the 2016 financial year, Huber Silica is expected to achieve sales of around $300m. Moving forward, Evonik expects to generate synergies of $20m by 2021.

The transaction is expected to be completed in the second half of 2017.

Related news

Related products

show more

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Related suppliers

Follow us

Products

View more

Webinars